Screener
Nuvation Bio NUVB Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -81%+1,484pp | -105%+5,658pp | -338.7%+7,189pp | -871%+25,009pp | -1,564.9%+35,909pp | |
| Net margin | -88.2%+1,325pp | -102.1%+5,432pp | -325.3%+6,888pp | -813.1%+23,807pp | -1,413.4%+34,177pp | |
| Returns | ||||||
| Return on equity | -47.8%+16.6pp | -39.5%+80.2pp | -53.2%+53.1pp | -52.5%+43.0pp | -64.4%+51.4pp | |
| Return on invested capital | -146.8%-39.9pp | -47.4%+86.1pp | -67%+51.1pp | -60.6%+43.4pp | -106.9%+24.9pp | |
| Efficiency | ||||||
| Asset turnover | 0.2×+0.2× | 0.3×+0.2× | 0.1×+0.1× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 8.4×-1.0× | 7.4×-1.6× | 7×-2.1× | 8.5×-1.1× | 9.4×-2.1× | |
| Leverage | ||||||
| Debt-to-equity | 0×-0.1× | 0.2×+0.2× | 0.2×+0.2× | 0.2×+0.2× | 0.2×+0.1× | |
| Per Share | ||||||
| Book value per share | $0.73-33.5% | $0.85-31.7% | $0.90-48.1% | $0.95-48.2% | $1.09+4.1% | |
| Valuation | ||||||
| Market capitalization | $2.15B+168% | $1.49B+150% | $3.07B+243% | $1.27B+126% | $697.54M+9.1% | |
| Price / sales | 12.6×-43.1× | 10.4×-44.0× | 48.8×-64.9× | 47.3×-212× | 48.6×-397× | |
| Price / book | 8.5×+6.3× | 4.7×+3.2× | 10×+8.1× | 3.9×+2.8× | 1.9×-0.6× |
FAQ
- What are Nuvation Bio's profit margins?
- Nuvation Bio (NUVB) runs a 54.3% gross margin and a -81.0% operating margin, with a -88.2% net margin.
- Where do Nuvation Bio's ratios come from?
- Every ratio is computed from Nuvation Bio's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
